Home›Stock Screener›Balaxi Pharmaceuticals

Balaxi Pharmaceuticals Share Price Today | Stock Price & Balaxi Pharmaceuticals Share Screener

BALAXI Pharmaceuticals
Live Share Price NSE
₹22.77
▲ 0.43 (1.92%)
2026-10-05 00:00:00

As of October 5, 2026, the live Balaxi Pharmaceuticals share price (NSE: BALAXI) is ₹22.77, up 1.92% from the previous close, with shares trading between ₹22.06 and ₹23.05 in today's trading session, and a 52-week range of ₹15.67–₹43.28. Check BALAXI 52-week performance for the annual price range and momentum. Use the Balaxi Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Balaxi Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹74 and net income of ₹1, with EBITDA of ₹3.

Balaxi Pharmaceuticals Market Cap ₹125.87 Cr.
BALAXI P/E Ratio (TTM) 52.32
Balaxi Pharmaceuticals P/B Ratio 0.51
EPS (TTM) ₹0.26
Dividend Yield -
Debt to Equity 0.23
BALAXI 52 Week High ₹43.28
Balaxi Pharmaceuticals 52 Week Low ₹15.67
Operating Margin -
Profit Margin 1.35%
BALAXI Revenue (TTM) ₹74.00
EBITDA ₹3.00
Net Income ₹1.00
Total Assets ₹337.00
Total Equity ₹249.00

Balaxi Pharmaceuticals Share Price Chart

Track the current stock price of Balaxi Pharmaceuticals with an interactive chart. Analyse BALAXI share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Balaxi Pharmaceuticals stock quote in one place.

The quote of ₹22.77 sits between the 52-week low of ₹15.67 and the 52-week high of ₹43.28, and the latest session moved 1.92% from the previous close.

Balaxi Pharmaceuticals Company Profile - Fundamental Screener

Screen Balaxi Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BALAXI shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE618N01022.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE618N01022

Balaxi Pharmaceuticals Balance Sheet Screener

Screen BALAXI balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹337, up from ₹310 in 2025.

Latest statistics put total assets at ₹337 and shareholder funds at ₹249, with a leverage ratio of 0.23.

Item 2026 2025 2024 2023 2022 2021 2020 2019

Assets

Total Assets 337 310 258 240 177 100 36 6
Current Assets 251 243 210 194 141 94 35 6
Fixed Assets 82 41 41 41 29 2 0 0

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0
Current Liabilities 26 24 3 4 0 0 0 0
Non-Current Liabilities 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 249 232 201 183 113 65 28 4
Share Capital 11 11 11 10 10 10 10 3
Reserves & Surplus 238 221 187 162 103 55 18 1

Balaxi Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Balaxi Pharmaceuticals income statement and profit fundamentals. Analyze BALAXI quarterly results. Balaxi Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹74 and net profit was ₹1, equal to earnings per unit of ₹0.11.

In that period expenses were ₹71, interest cost ₹1 and tax ₹1. The next period listed, 2026-Jun, shows revenue of ₹80 and net profit of ₹1.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar

Revenue and Expenses

Revenue 74 80 75 69 58 73 59 64 73 77 81 65 61 62 93
Expenses 71 76 64 67 55 69 46 56 67 69 68 104 44 47 78

Operating Costs and Margins

EBITDA 3 4 11 2 3 3 13 8 7 8 13 -39 17 15 15
Operating Profit % 0.00% 6.00% 16.00% 6.00% 2.00% 4.00% 23.00% 15.00% 14.00% 5.00% 16.00% -57.00% 20.00% 22.00% 13.00%
Depreciation 1 1 1 1 1 1 1 1 1 1 1 0 1 1 0
Interest 1 1 1 1 1 1 1 0 0 1 0 0 0 0 0

Profit and Earnings

Profit Before Tax 1 2 10 1 1 2 12 7 6 6 11 -39 16 14 15
Tax 1 1 1 1 1 1 1 1 1 1 3 2 1 1 2
Net Profit 1 1 9 0 0 0 11 7 5 5 8 -41 14 14 13
EPS 0.11 0.24 1.56 0.05 0.04 0.06 10.41 1.17 0.84 0.97 8.01 -40.49 14.10 13.29 12.71

Balaxi Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen BALAXI cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹5, and net cash flow was an outflow of ₹25.

Over the same period, investing activities used ₹21 and financing activities provided ₹0.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March

Cash from Operations and Investing

Operating Activities -5 -35 5 6 34 0 -14 -2
Investing Activities -21 -22 -1 -11 -29 -6 0 0

Financing and Net Cash

Financing Activities 0 34 30 26 0 4 18 0
Net Cash Flow -25 -23 34 21 6 -2 4 -2

Balaxi Pharmaceuticals Shareholding Pattern Screener

See Balaxi Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Balaxi Pharmaceuticals promoter holding and ownership changes for BALAXI on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 65.99%, foreign institutions 0.00%, domestic institutions 2.56% and the public 24.41%, spread across 15,176 shareholders.

The shareholder count was 15,176 in 2026-Mar, compared with 14,682 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Apr

Promoter Holding

Promoter Holding 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 66.36% 66.36%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 1.74% 0.00% 0.00%
DII Holding 2.56% 2.56% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 24.41% 24.43% 9.82% 16.14% 20.03% 22.39% 7.98% 7.98%
Other Holding 7.03% 7.02% 24.17% 17.84% 13.95% 9.86% 25.64% 25.64%
Shareholder Count 15,176 14,682 9,994 13,737 14,620 15,085 5,132 5,132

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Balaxi Pharmaceuticals. Balaxi Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.50 0.47%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Balaxi Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Balaxi Pharmaceuticals stock. Check BALAXI index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Balaxi Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Balaxi Pharmaceuticals Market Events Screener - Corporate Actions

Get Balaxi Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Balaxi Pharmaceuticals stock events that may affect BALAXI share price, along with derivatives, futures and options activity and sector gainers.

12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 5, 2026, with a record date of August 5, 2026.

It is followed by Quarterly Result Announcement dated May 28, 2026 and Quarterly Result Announcement dated January 28, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-08-05 2026-08-05 Quarterly Result Announcement NA -1.80%
2026-05-28 2026-05-28 Quarterly Result Announcement NA -14.25%
2026-01-28 2026-01-28 Quarterly Result Announcement NA 2.45%
2025-11-11 2025-11-11 Quarterly Result Announcement NA -3.16%
2025-08-05 2025-08-05 Quarterly Result Announcement NA -3.91%
2025-05-30 2025-05-30 Quarterly Result Announcement NA -6.82%
2025-02-10 2025-02-10 Quarterly Result Announcement NA 2.44%
2024-11-05 2024-11-05 Quarterly Result Announcement NA -1.03%
2024-08-23 2024-08-23 Annual General Meeting NA -5.24%
2024-05-30 2024-05-30 Split 2:10 451.29%
2022-07-01 2022-07-04 Dividend ₹ 0.50 /share -13.13%
2020-10-07 2020-10-07 Change Of Name NA 0.00%

Balaxi Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen BALAXI competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 440,158 36.83 61,674 12.69% 11,565 47.42
Divis Laboratories 248,240 86.00 11,067 13.95% 2,568 58.71
Torrent Pharmaceuticals 183,908 86.72 13,886 20.34% 2,138 48.14
Zydus Life Science 115,710 25.96 27,658 17.64% 5,026 61.81
Cipla 110,297 33.29 29,045 2.24% 3,870 44.03
Laurus Labs 106,706 98.39 6,868 22.01% 890 58.00
Dr Reddys Laboratories 102,666 32.77 35,059 3.90% 4,158 69.59
Mankind Pharma 102,357 50.84 14,636 14.85% 1,938 64.24
Aurobindo Pharma 96,589 26.41 34,145 5.56% 3,503 54.69
Lupin 93,287 16.97 29,039 26.75% 5,356 34.02

Balaxi Pharmaceuticals Company Announcements - News & Reports Screener

Screen BALAXI latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 2, 2026.

The next most recent announcements are dated September 7, 2026 and August 31, 2026.

Date Update Actions
2026-10-02 Trading Window -
2026-09-07 Updates -
2026-08-31 General Updates -
2026-08-24 Change in Director(s) -
2026-08-24 Shareholders meeting -
2026-08-24 Shareholders meeting -
2026-08-14 Copy of Newspaper Publication -
2026-08-11 Copy of Newspaper Publication -
2026-08-10 Corrigendum -
2026-08-07 Updates -
2026-08-06 Investor Presentation -
2026-08-06 Copy of Newspaper Publication -
2026-08-05 Outcome of Board Meeting -
2026-08-05 Outcome of Board Meeting -
2026-08-05 Updates -
2026-08-01 Copy of Newspaper Publication -
2026-07-31 Updates -
2026-07-31 Shareholders meeting -
2026-07-20 Copy of Newspaper Publication -
2026-07-14 Reply to Clarification- Financial results -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹22.77, within a 52-week range of ₹15.67 to ₹43.28. The P/E ratio is 52.32 and the P/B ratio is 0.51, with earnings per unit of ₹0.26. Market capitalisation stands at ₹125.87 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE. Key statistics were last updated on October 5, 2026. This page covers 8 balance sheet periods, 15 income statement periods, 8 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.